Anticancer Effect of Sirolimus in Renal Allograft Recipients With De Novo Malignancies

Transplantation Proceedings

Volumn 39, Issue 9, 2007, Pages 2736-2739

  Boratynska M ^a   Watorek, E ^a   Smolska, D ^a   Patrzalek D ^a   Klinger, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GINGIVA TUMOR; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KAPOSI SARCOMA; KIDNEY ALLOGRAFT; KIDNEY CARCINOMA; LARYNX CANCER; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 36048952768     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.08.078     Document Type: Article

References (17)

1. Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 33 (2007) 78
2. Vega F., Medeiros L.J., and Leventaki V. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66 (2006) 6589
3. Luan F.L., Ding R., and Sharma V.K. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63 (2003) 917
4. Mita M.M., Mita A., and Rovinsky E.K. Mamalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4 (2003) 126
5. Campistol J.M., Albanell J., and Arns W. Use of proliferation signal inhibitors in the management of post-transplant malignacies-clinical guidance. Nephrol Dial Transplant 22 Suppl1 (2007) 136
6. Raymond E., Alexandre J., and Faivre S. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336
7. Ghobrial I.M., Habermann T.M., and Maurer M.J. Prognostic analysis for survival in adults solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 23 (2005) 7574
8. Stallone G., Schena A., and Infante B. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
9. Campistol J., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a succesful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
10. Zmonarski S., Boratynska M., and Rabczynski J. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37 (2005) 964
11. Sanches-Fructuoso A., Conesa J., and Perez Florez I. Conversion to sirolimus in renal transplant patients. Transplant Proc 38 (2006) 2451
12. Jimenez-Rivera C., Avitzur Y., and Fecteau A. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8 (2004) 243
13. Zaltzman J., Prasad R., and Chun K. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 20 (2005) 1748
14. Cullis B., D'Souza R., and McCullagh P. Sirolimus induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47 (2006) E67
15. Kahan B.D., Yakupoglu Y.K., and Schoenberg L. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80 (2005) 749
16. Koehl G.E., Andrassy J., and Guba M. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319
17. Guba M., Koehl G.E., and Neppl E. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18 (2005) 89